Nephrolithiasis with dorzolamide

Archives of Ophthalmology

Volumn 117, Issue 8, 1999, Pages 1087-

  Carlsen, Jeff ^b   Durcan, Jane ^a   Zabriskie, Norm ^b   Swartz, Mano ^b   Crandall, Alan ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; CARBONATE DEHYDRATASE INHIBITOR; DORZOLAMIDE; METHAZOLAMIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; CASE REPORT; FEMALE; GLAUCOMA; HUMAN; MALE; NEPHROLITHIASIS; PRIORITY JOURNAL; RETINITIS PIGMENTOSA; STONE FORMATION;

EID: 0345062330     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.117.8.1087     Document Type: Article

References (4)

1. Bartlett JD, Jaanus SD. Clinical Ocular Pharmacology. 3rd ed. Newton, Mass: Butterworth-Heineman; 1995:211-222.
2. Wilkerson M, Cyrlin M, Lippa EA, et al. Four-week safely study and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor. Arch Ophthalmol. 1993;111: 1343-1350.
3. Consensus conference: prevention and treatment of kidney stones. JAMA. 1988;260:977-981.
4. Greco MJ. Official release from the Associate Director of Medical Services for the manufacturer of Trusopt, dorzolamide. West Pointe, Pa: Merck & Co Inc; July 18, 1995.